Status:
RECRUITING
Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Amyloid Cardiomyopathy
Eligibility:
All Genders
18+ years
Brief Summary
Cardiac transthyretin amyloidosis (ATTR), caused by ventricular depositions of misfolded transthyretin, results in an infiltrative cardiomyopathy, progressing from pronounced myocardial wall thickenin...
Detailed Description
Cardiac transthyretin amyloidosis (ATTR), the most common amyloidosis form with cardiac involvement, is caused by tissue deposition of misfolded TTR, a transport Protein for thyroxine and retinol. Ven...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of amyloidosis w/wo cardiac involvement
- General Consent
Exclusion
- Inability to give consent or existence of a written or documented oral refusal of the data subject.\<18 years of age
Key Trial Info
Start Date :
February 22 2001
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2031
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04776824
Start Date
February 22 2001
End Date
May 1 2031
Last Update
May 6 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
USB
Basel, Switzerland, 4031
2
Department of Cardiology, University Hospital Bern, Inselspital, Bern
Bern, Switzerland, 3010
3
HUG
Geneva, Switzerland, 1211
4
CHUV
Lausanne, Switzerland, 1011